Since the development of prazosin some 25 years ago, the most widely used agents for BPH are alpha-adrenergic blockers (e.g. doxazosin and tamsulosin) and 5alpha-reductase inhibitors (e.g. finasteride).

In an effort to tackle this mature market, recent trends have moved towards the use of combination drug strategies, the treatment of co-morbid illnesses and a drive towards getting silent sufferers to present for treatment.

Market opportunities for BPH include:

• Agents with no sexual side effects in these patients who often have co-morbid sexual dysfunction
• Combination therapies to treat both symptoms and prostate size
• Drugs that could treat the obstructive symptoms of BPH and irritative symptoms of bladder dysfunction
• Treatments aimed at disease prevention

For existing products URODOC could re-energise existing communication programme. We understand that product redefinition could be the key to your success, and we can assist in market expansion by:

• product recreation
• product differentiation and
• product 'evergreening' strategies